6 Results

People

  1. Lesokhin
    Lesokhin
  2. Wolchok
    Wolchok
  3. Postow
    Postow
  4. Agunwamba
    Agunwamba
  5. Callahan
    Callahan
  6. Gordon
    Gordon
  7. Kronenberg
    Kronenberg
  8. Rizvi
    Rizvi
  9. Segal
    Segal
  10. Yuan
    Yuan

Groups

  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (6)
  3. GSK Faculty (6)
  4. Hematologic Malignancies Research (6)
  5. Hematologic Malignancies, Division of (6)
  6. Melanoma and Immunotherapeutics Service (6)
  7. Myeloma (6)
  8. Solid Tumor Oncology Division (6)
  9. Melanoma Disease Management Team (5)
  10. Advanced Practice Providers (3)
  1. "Hematologic Malignancies Research"
  2. "2014"
  3. "Jedd Wolchok"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (2)
  3. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (6)
  3. GSK Faculty (6)
  4. Hematologic Malignancies Research (6)
  5. Hematologic Malignancies, Division of (6)
  6. Melanoma and Immunotherapeutics Service (6)

More Groups

People
  1. Alexander Lesokhin (6)
  2. Jedd Wolchok (6)
  3. Michael Postow (5)
  4. Blessing Agunwamba (3)
  5. Margaret Callahan (3)
  6. Naiyer Rizvi (3)

More People

Years
  1. 2014 (6)
Publications
  1. Annals of Oncology (1)
  2. Asia-Pacific Journal of Clinical Oncology (1)
  3. Cancer Immunology Research (1)
  4. Journal of Clinical Oncology (1)
  5. Methods in Molecular Biology (1)
  6. Pocket Oncology (1)
Publishers
  1. American Association for Cancer Research (1)
  2. American Society of Clinical Oncology (1)
  3. Humana Press Inc (1)
  4. Oxford University Press (1)
  5. Wiley Blackwell (1)
  6. Wolters Kluwer Health | Lippincott Williams & Wilkins (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-programmed death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Gordon, R.; Seal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Cancer immunology
    Book Section

    Hobbs, G.; Lesokhin, A. M.; Zamarin, D.; Wolchok, J. D.
    In Drilon, A. E.; Postow, M. A.; Krug, L. M. (Eds.) Pocket Oncology (2014)

    Fulltext@MSK | Save
  • Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes
    Journal Article

    Kitano, S.; Postow, M. A.; Ziegler, C. G. K.; Kuk, D.; Panageas, K. S.; Cortez, C.; Rasalan, T.; Adamow, M.; Yuan, J. D.; Wong, P.; more...
    Cancer Immunology Research (2014)

    Fulltext@MSK | Save
  • Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma
    Journal Article

    Postow, M. A.; Yuan, J.; Kitano, S.; Lesokhin, A. M.; Wolchok, J. D.
    Methods in Molecular Biology (2014)

    Fulltext@MSK | Save